FAQ

FAQ published on January 20, 2020
Dr. Komrokji discusses treatment management issues when switching from ruxolitinib to fedratinib.
FAQ published on January 20, 2020
Dr. Komrokji discusses whether or not fedratinib can be used in the upfront setting for the treatment of myelofibrosis.
FAQ published on January 20, 2020
Dr. Komrokji discusses how tagraxofusp-erzs is used for the treatment of myelofibrosis and if there is a connection between BPDCN and myelofibrosis.
FAQ published on January 20, 2020
Dr. Komrokji discusses how to determine the best treatment options for each patient using a patient-centered approach.
FAQ published on January 20, 2020
Dr. Komrokji discusses the differences in the adverse event profile between fedratinib and ruxolitinib.
FAQ published on January 20, 2020
Dr. Komrokji discusses the next steps in myelofibrosis research and understanding the biology of the disease.
FAQ published on January 20, 2020
Dr. Komrokji discusses where the JAK inhibitors fit in the treatment of myelofibrosis.
FAQ published on January 20, 2020
Dr. Komrokji discusses how fedratinib fits as a treatment option for myelofibrosis.
FAQ published on January 20, 2020
Dr. Komrokji discusses the importance of obtaining blood counts before initiating therapy with ruxolitinib and subsequently every two to four weeks thereafter.
FAQ published on January 20, 2020
Dr. Komrokji discusses the importance of testing thiamine levels before administering fedratinib.

Results 1 - 10 of 10